The guidelines are a first-of-its-kind effort to establish recommendations for the medical management of HS in seven ...

In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab ...

About 43% of patients with sarcoidosis received treatment within 1 year of diagnosis, according to study findings published in Chest. Researchers evaluated treatment rates, treatm ...

AbbVie (ABBV) continues to dominate the adalimumab market with 72% share in the U.S., despite biosimilar threats gaining ground. Read more here.

A study from Spain found a subcutaneous tocilizumab biosimilar to be cost-effective when treating patients with rheumatoid ...

AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira sales drop.

USA: A recent post hoc analysis of two randomized clinical trials has provided insight into the role of C-reactive protein ...

The sequence of biologic treatments in patients with inflammatory bowel disease significantly affects their risk of adverse ...

J&J will protect the branded anti-interleukin (IL)-12/23 biologic Stelara against sales erosion from biosimilars.

Long-term TNFi use in patients with psoriasis was not associated with a higher risk of cancer, including lymphoma, prostate cancer, and breast cancer.

For patients with psoriatic arthritis, switching directly from adalimumab to tofacitinib with no washout period presents no ...